China’s Mindrank raises $52M series B to advance oral GLP-1
· tamra sami
AI Briefing
- • Mindrank AI Ltd raises $52M series B funding to advance MDR-001, an oral GLP-1 receptor agonist.
- • MDR-001 is in phase III trials for obesity in China, a promising therapeutic area for the company.
- • The AI-discovered compound is a significant step towards treating obesity, a growing health concern globally.
Context
Mindrank AI Ltd. has completed a series B funding round, raising $52 million. The company will use this funding to advance its oral small-molecule GLP-1 receptor agonist, MDR-001.
The funding is significant as MDR-001 is currently in phase III trials for obesity in China, and the new investment will help support its development.
Advertisement